Logo-bi
Original Research

1. Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe₃O₄ in T47D Breast Cancer Cell Line
Zohreh Ebrahimnezhad, Nosratollah Zarghami*, Manoutchehr Keyhani, Soumaye Amirsaadat, Abolfazl Akbarzadeh, Mohammad Rahmati, Zohreh Mohammad Taheri, Kazem Nejati-Koshki
Bioimpacts. 2013;3(2): 67-74. doi: 10.5681/bi.2013.005
PMCID: PMC3713872     PMID: 23878789     Scopus ID: 84881534495    
Article
XML
Cited By:
62
11
0
Retraction

2. Retraction Note: Inhibition of hTERT Gene Expression by SilibininLoaded PLGA-PEG-Fe₃O₄ in T47D Breast Cancer Cell Line
Zohreh Ebrahimnezhad, Nosratollah Zarghami*, Manoutchehr Keyhani, Soumaye Amirsaadat, Abolfazl Akbarzadeh, Mohammad Rahmati, Zohreh Mohammad Taheri, Kazem Nejati-Koshki
Bioimpacts. 2018;8(4): 321. doi: 10.15171/bi.2018.34
PMCID: PMC6209827     PMID: 30397586     Scopus ID: 85056145531    
Article
PDF
Full Text
XML
Cited By:
0
0
1
Original Article

3. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy
Mina Yousefnezhad, Soodabeh Davaran* ORCID, Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Bioimpacts. 2023;13(3): 241-253. doi: 10.34172/bi.2023.24252
PMCID: PMC10329752     PMID: 37431480     Scopus ID: 85157052599    
Article
PDF
Full Text
XML
Cited By:
3
0
1
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge